戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              NIPT data showed recurrent gains and losses in primary m
2                                              NIPT for fetal aneuploidy screening (chromosomes 13, 18,
3                                              NIPT profiles from patients with confirmed malignancies
4                     From a cohort of 125,426 NIPT results, 3757 (3%) were positive for 1 or more aneu
5 NAIT cases will become apparent and accurate NIPT blood group antigen typing results are crucial for
6 used in our standard pipeline for aneuploidy NIPT detected 15/18 (83%) samples with pathogenic rearra
7        Overall, this NGS-based fetal antigen NIPT assay had high performance that was comparable to i
8 results suggest that NGS-based fetal antigen NIPT may identify more fetuses at risk for hemolytic dis
9 ted a next generation sequencing-(NGS) based NIPT assay using quantitative counting template (QCT) te
10 s among 39 cases of multiple aneuploidies by NIPT, 18% [95% CI, 7.5%-33.5%]).
11 enotypes can be collected alongside clinical NIPT, the potential for large GWAS.
12 xed with far-larger amounts of maternal DNA, NIPT requires a minimum fraction of the circulating cfDN
13                                       During NIPT in over 4000 prospective pregnancies by parallel se
14                Furthermore, to be effective, NIPT must be able to detect chromosomal rearrangements a
15                                           In NIPT it is important to prevent both false-positive resu
16              Copy-number changes detected in NIPT sequencing data in the known cancer cases were comp
17 omes-also known as chromosomal phase-to make NIPT analyses more conclusive.
18 ospectively included from a Dutch nationwide NIPT implementation study, TRIDENT-2.
19  pregnant women, a low percentage (0.02%) of NIPT results were assessed as indicative of a maternal m
20 nology have further enhanced the accuracy of NIPT.
21                         Clinical adoption of NIPT for the detection of fetal antigens for both alloim
22 ome-wide copy-number changes in the original NIPT samples and in subsequent serial samples from indiv
23  R package that implements several published NIPT analysis methods.
24 ncers most frequently occurred with the rare NIPT finding of more than 1 aneuploidy detected (7 known
25  tumors in pregnant women undergoing routine NIPT.
26 g a UK Biobank reference panel and simulated NIPT data, we see accurate imputation of the mother (0.2
27                             Because standard NIPT can only detect the majority of larger (>6 Mb) chro
28        Here, we detail malignancy suspicious-NIPT cases, and describe the clinical characteristics, c
29 agnostic routing after malignancy suspicious-NIPT faces many challenges.
30                        Malignancy suspicious-NIPT results were reported in 0.03% after genome-wide NI
31  targeted NIPT, 0.005% malignancy suspicious-NIPT results were reported, in 2/3 patients a malignancy
32                               After targeted NIPT, 0.005% malignancy suspicious-NIPT results were rep
33 y detection on noninvasive prenatal testing (NIPT) and occult maternal malignancies may explain resul
34 ing cell free non-invasive prenatal testing (NIPT) data.
35                Noninvasive prenatal testing (NIPT) for fetal aneuploidy by scanning cell-free fetal D
36                Noninvasive prenatal testing (NIPT) for fetal aneuploidy screening using cell-free DNA
37 nal cfDNA for non-invasive prenatal testing (NIPT) of aneuploidy is widely available.
38               Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is b
39               Non-invasive prenatal testing (NIPT) to detect fetal aneuploidy by sequencing the cell-
40  enabled safe, noninvasive prenatal testing (NIPT).
41 be guided by tumor-specific hallmarks in the NIPT profile.
42 uent tumor biopsies were concordant with the NIPT plasma GR profiles.
43 nconclusive aneuploidy determination through NIPT.
44 sed for Rhesus antigen D blood group typing, NIPT now covers various blood group antigens.
45                    In a clinical validation, NIPT results were 100% concordant with corresponding neo
46 NA fractions and complex genetic variations, NIPT has become essential in managing alloimmunized preg
47 e seen in 23 of 48 patients with genome-wide NIPT, and a malignancy was confirmed in 16 patients (16/
48 lts were reported in 0.03% after genome-wide NIPT, and malignancies confirmed in 16 patients (16/48,
49                                Patients with NIPT results indicative of a malignancy referred for tum